Advertisement
U.S. markets open in 3 hours 44 minutes

Regulus Therapeutics Inc. (RGLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.3600+0.2500 (+11.85%)
At close: 04:00PM EDT
2.3300 -0.03 (-1.27%)
Pre-Market: 04:01AM EDT

Regulus Therapeutics Inc.

4224 Campus Point Court
Suite 210
San Diego, CA 92121
United States
858 202 6300
https://www.regulusrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees29

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph P. Hagan M.B.A.CEO & Director920.73kN/A1969
Ms. Crispina Calsada CPAChief Financial Officer500.87kN/A1970
Mr. Christopher Ray Aker J.D.Senior VP, General Counsel & Corporate Secretary524.79kN/A1961
Dr. Preston S. Klassen M.D., M.H.S.President, Head of Research & Development and DirectorN/AN/A1969
Mr. Daniel J. PenksaVP of Finance & ControllerN/AN/A1986
Dr. Claire Susan Padgett M.S., M.T., Ph.D.Senior Vice President of Clinical OperationsN/AN/AN/A
Dr. Rekha Garg M.D., M.S.Senior Vice President of Clinical Development & RegulatoryN/AN/AN/A
Mr. Edmund Lee Ph.D.Vice President of Translational MedicineN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Corporate Governance

Regulus Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.